Intention-to-treat analysis keeps all trial data, showing true drug effects, even with dropouts. It contrasts with per-protocol analysis, where dropout data is excluded, possibly skewing results.
In the full intention-to-treat population for the efficacy analysis, 230 of 255 patients (90.2%) who received risankizumab and 193 of 265 patients (72.8%) who received ustekinumab completed all the ...
Per-protocol analysis excludes noncompliant clinical trial participants' data. Mixing per-protocol with other analyses gives a clearer intervention picture. Regulators typically reject sole ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback